(GOCO) GoHealth - Ratings and Ratios

GoHealth, Inc. (NASDAQ:GOCO) is a leading health insurance marketplace and Medicare-focused digital health company in the United States. The company operates a sophisticated technology platform that utilizes machine-learning algorithms to analyze insurance behavioral data, enabling personalized recommendations for individuals seeking health insurance plans tailored to their needs. GoHealth specializes in Medicare plans, including Medicare Advantage, Medicare Supplement, Prescription Drug Plans, and Medicare Special Needs Plans. Additionally, the company provides partner marketing services to enhance distribution channels. Its products are sold directly through insurance carriers, its online platform, and a network of independent and external agencies. Founded in 2001, GoHealth is headquartered in Chicago, Illinois, and has established itself as a key player in the Medicare insurance market. Web URL: https://www.gohealth.com

GoHealths platform is designed to streamline the insurance selection process, leveraging data analytics to match consumers with optimal plans based on their specific needs and preferences. The companys focus on Medicare reflects the growing demand for senior health insurance solutions, driven by an aging U.S. population. By integrating advanced technology with a customer-centric approach, GoHealth aims to improve accessibility and affordability in the health insurance market. Its partner marketing services further expand its reach, enabling carriers to enhance their distribution capabilities and connect with a broader audience.

3-Month Forecast: Based on and , GoHealths stock is expected to experience volatility in the near term. The stock is currently trading below its SMA20 and SMA50 but remains above its SMA200, indicating potential support at higher levels. The ATR of 1.31 suggests moderate price movement. From a perspective, the companys forward P/E of 555.56 signals high expectations for future earnings, though the current P/E of 0.00 reflects ongoing challenges in profitability. The P/B ratio of 0.87 and P/S ratio of 0.60 suggest undervaluation relative to book value and sales, respectively. However, the negative RoE of -7.98 raises concerns about profitability. Overall, the stock may consolidate in the short term, with potential upside driven by improved earnings visibility and execution on Medicare growth initiatives.